CTLA4 and melanoma: More specifically, increased BMI is associated with increased PFS and overall survival (OS) in male melanoma patients receiving the anti-CTLA4 agent ipilimumab plus the chemotherapeutic agent dacarbazine or PD1-PDL1 axis inhibition.